Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Thomas S. Y. Chan, Stephen W. Marcella, Harinder Gill, Yu-Yan Hwang & Yok-Lam Kwong. (2016) Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. Journal of Medical Economics 19:1, pages 77-83.
Read now
Read now
Ahmet Soysal. (2015) Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infection and Drug Resistance 8, pages 321-331.
Read now
Read now
Anita H. Sung, Stephen W. Marcella & Yang Xie. (2015) An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. Journal of Medical Economics 18:5, pages 341-348.
Read now
Read now
Isabel Sánchez-Ortega, Beatriz Patiño, Carmen Muñoz, Montserrat Arnan, Teresa Peralta, Ana Clopés, Alberto Fernández de Sevilla & Rafael F. Duarte. (2013) Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. Journal of Medical Economics 16:6, pages 736-743.
Read now
Read now
K. Athanasakis, I. Petrakis & J. Kyriopoulos. (2013) Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: A cost-effectiveness analysis in Greece. Journal of Medical Economics 16:5, pages 678-684.
Read now
Read now
George Papadopoulos, Sheena Hunt & Manishi Prasad. (2013) Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. Journal of Medical Economics 16:3, pages 374-380.
Read now
Read now
Tzi Bun Ng, Randy Chi Fai Cheung, Xiu juan Ye, Evandro Fei Fang, Yau Sang Chan, Wen Liang Pan, Xiu Li Dan, Cui Ming Yin, Sze Kwan Lam, Peng Lin, Patrick Hung Kui Ngai, Li Xin Xia, Fang Liu, Xiu Yun Ye, He Xiang Wang & Jack Ho Wong. (2012) Pharmacotherapy approaches to antifungal prophylaxis. Expert Opinion on Pharmacotherapy 13:12, pages 1695-1705.
Read now
Read now
Articles from other publishers (11)
Jessica Caro, Rafael Madero-Marroquin, Nicole Zubizarreta, Erin Moshier, Douglas Tremblay, Alex Coltoff, Guido Lancman, Risa Fuller, Meenakshi Rana, John Mascarenhas & Samantha E. Jacobs. (2022) Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients. Clinical Lymphoma Myeloma and Leukemia 22:12, pages 903-911.
Crossref
Crossref
Thomas Harrison & David Partridge. (2022) Should serum biomarker monitoring replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy? A PRO/CON debate. JAC-Antimicrobial Resistance 4:4.
Crossref
Crossref
Changcheng Shi, Jian Ye, Yaping Xie, Rong Dong, Weizhong Jin, Linling Wang, Yingying Fang, Qiyuan Shan & Nengming Lin. (2022) Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China. Frontiers in Public Health 10.
Crossref
Crossref
Jean-Pierre Gangneux, Christophe Padoin, Mauricette Michallet, Emeline Saillio, Alexandra Kumichel, Régis Peffault de La Tour, Patrice Ceballos, Thomas Gastinne & Arnaud Pigneux. (2020) Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study. Journal of Fungi 6:4, pages 281.
Crossref
Crossref
L. Tang, X.-F. Yang, M. Qiao, L. Zhang, X.-W. Tang, H.-Y. Qiu, D.-P. Wu & A.-N. Sun. (2018) Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study. Journal de Mycologie Médicale 28:2, pages 379-383.
Crossref
Crossref
J.-P. Gangneux, M.-E. Bougnoux, C. Hennequin, C. Godet, J. Chandenier, D.W. Denning & B. Dupont. (2016) An estimation of burden of serious fungal infections in France. Journal de Mycologie Médicale 26:4, pages 385-390.
Crossref
Crossref
Johan Lundberg, Martin H?glund, Magnus Bj?rkholm & ?rjan ?kerborg. (2014) Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden. Clinical Drug Investigation 34:7, pages 483-489.
Crossref
Crossref
Sebastian M. Heimann, Oliver A. Cornely, Maria J. G .T. Vehreschild, Jan Glossmann, Matthias Kochanek, Karl-Anton Kreuzer, Michael Hallek & J?rg J. Vehreschild. (2014) Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses 57:2, pages 90-97.
Crossref
Crossref
Me‐Linh Luong, Shahid Husain & Coleman Rotstein. (2013) Pharmacoeconomic assessment of therapy for invasive aspergillosis. Mycoses 56:3, pages 338-349.
Crossref
Crossref
Angelika Böhme, Johannes Atta, Sabine Mousset, Birgit Ehlken, Margarita Shlaen, Gesine Bug, Hubert Serve & Dieter Hoelzer. (2011) Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy – retrospective analysis of changes over 3 yr in a German hospital. European Journal of Haematology 88:1, pages 68-77.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2011) Posaconazole. PharmacoEconomics 29:3, pages 251-268.
Crossref
Crossref